Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$0.66 -0.1%	$0.64	$0.51 ▼ $1.80	$63.13M	0.29	653,721 shs	221,869 shs
CLSD Clearside Biomedical	$0.79	$0.83	$0.70 ▼ $1.65	$61.39M	2.06	360,492 shs	95,995 shs
DRRX DURECT	$0.66 +3.3%	$0.63	$0.48 ▼ $1.74	$20.38M	0.59	85,352 shs	232,172 shs
MCRB Seres Therapeutics	$7.73 +5.6%	$8.30	$6.53 ▼ $30.60	$67.48M	2.62	135,365 shs	65,375 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	+1.83%	+0.15%	-0.59%	-6.76%	-36.96%
CLSD Clearside Biomedical	-0.82%	-2.47%	-10.11%	-21.78%	-33.05%
DRRX DURECT	+0.63%	+10.54%	+0.87%	-20.55%	-64.29%
MCRB Seres Therapeutics	-2.40%	-11.38%	-1.88%	-53.05%	-45.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASRT Assertio	1.5914 of 5 stars	3.5	1.0	0.0	0.0	0.8	1.3
CLSD Clearside Biomedical	2.6713 of 5 stars	3.5	5.0	0.0	3.2	0.0	0.0
DRRX DURECT	0.6284 of 5 stars	0.0	3.0	4.4	0.6	0.0	0.0
MCRB Seres Therapeutics	2.2017 of 5 stars	2.9	3.0	4.6	0.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	3.00	Buy	$2.75	317.24% Upside
CLSD Clearside Biomedical	3.00	Buy	$4.80	507.59% Upside
DRRX DURECT	2.00	Hold	N/A	N/A
MCRB Seres Therapeutics	1.75	Reduce	$73.67	853.00% Upside

Current Analyst Ratings Breakdown

Latest DRRX, ASRT, CLSD, and MCRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
5/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.50 ➝ $3.50
5/16/2025	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
5/15/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
5/13/2025	ASRT Assertio	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
4/8/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/31/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/28/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/28/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00
3/27/2025	DRRX DURECT	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$119.00M	0.53	$0.05 per share	12.87	$1.27 per share	0.52
CLSD Clearside Biomedical	$1.66M	36.98	N/A	N/A	($0.51) per share	-1.55
DRRX DURECT	$2.03M	10.04	N/A	N/A	$0.29 per share	2.26
MCRB Seres Therapeutics	$126.32M	0.53	N/A	N/A	$1.61 per share	4.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$21.58M	-$0.32	N/A	21.97	N/A	-25.72%	-24.87%	-10.87%	8/6/2025 (Estimated)
CLSD Clearside Biomedical	-$34.35M	-$0.41	N/A	N/A	N/A	-818.57%	N/A	-114.23%	8/11/2025 (Estimated)
DRRX DURECT	-$8.32M	-$0.15	N/A	N/A	N/A	-91.54%	-267.36%	-64.00%	8/12/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-41,084.76%	-55.87%	8/12/2025 (Estimated)

Latest DRRX, ASRT, CLSD, and MCRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CLSD Clearside Biomedical	-$0.12	-$0.11	+$0.01	-$0.11	$0.20 million	$2.33 million
5/12/2025	Q1 2025	ASRT Assertio	-$0.06	-$0.14	-$0.08	-$0.14	$27.52 million	$26.49 million
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
3/27/2025	Q4 2024	CLSD Clearside Biomedical	-$0.13	-$0.10	+$0.03	-$0.10	$0.27 million	$0.31 million
3/26/2025	Q4 2024	DRRX DURECT	$0.06	-$0.06	-$0.12	$0.24	$6.91 million	$2.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
DRRX DURECT	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.36	1.66	1.35
CLSD Clearside Biomedical	N/A	3.19	3.19
DRRX DURECT	N/A	1.23	1.22
MCRB Seres Therapeutics	N/A	2.11	2.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
CLSD Clearside Biomedical	18.75%
DRRX DURECT	28.03%
MCRB Seres Therapeutics	59.34%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	4.00%
CLSD Clearside Biomedical	6.20%
DRRX DURECT	3.20%
MCRB Seres Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	95.78 million	91.95 million	Optionable
CLSD Clearside Biomedical	30	77.71 million	72.89 million	Optionable
DRRX DURECT	80	31.04 million	30.05 million	Optionable
MCRB Seres Therapeutics	330	8.73 million	8.32 million	Optionable

DRRX, ASRT, CLSD, and MCRB Headlines

Recent News About These Companies

Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50-Day Moving Average - Here's What Happened

June 5, 2025 | marketbeat.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Update

June 3, 2025 | marketbeat.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of "Reduce" by Brokerages

May 29, 2025 | marketbeat.com

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 27, 2025 | globenewswire.com

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?

May 23, 2025 | zacks.com

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average - Here's Why

May 19, 2025 | marketbeat.com

Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade

May 16, 2025 | zacks.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript

May 9, 2025 | insidermonkey.com

Chardan Capital Downgrades Seres Therapeutics (MCRB)

May 9, 2025 | msn.com

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

May 7, 2025 | seekingalpha.com

Seres Therapeutics reports Q1 EPS $3.75, consensus $1.97

May 7, 2025 | msn.com

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025 | globenewswire.com

Seres Therapeutics Q1 2025 Earnings Preview

May 6, 2025 | msn.com

Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 5.09%

May 6, 2025 | aaii.com

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

April 29, 2025 | globenewswire.com

Petri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock split

April 24, 2025 | bizjournals.com

Seres Therapeutics trading resumes

April 24, 2025 | markets.businessinsider.com

Seres Therapeutics trading halted, volatility trading pause

April 24, 2025 | markets.businessinsider.com

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

April 23, 2025 | globenewswire.com

Seres Therapeutics trading halted, news pending

April 22, 2025 | markets.businessinsider.com

Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Up 10.81%

April 21, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRRX, ASRT, CLSD, and MCRB Company Descriptions

Assertio NASDAQ:ASRT

$0.66 0.00 (-0.14%)

Closing price 04:00 PM Eastern

Extended Trading

$0.68 +0.02 (+3.63%)

As of 06:34 PM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Clearside Biomedical NASDAQ:CLSD

$0.79 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$0.78 -0.01 (-0.89%)

As of 04:16 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

DURECT NASDAQ:DRRX

$0.66 +0.02 (+3.32%)

As of 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Seres Therapeutics NASDAQ:MCRB

$7.73 +0.41 (+5.60%)

Closing price 04:00 PM Eastern

Extended Trading

$7.37 -0.36 (-4.64%)

As of 06:06 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time